Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	32.06B
Revenue (ttm)	11.58B
Net Income (ttm)	570.05M
Shares Out	231.00M
EPS (ttm)	2.47
PE Ratio	56.25
Forward PE	n/a
Dividend	2.00 (1.47%)
Ex-Dividend Date	Oct 28, 2024

Volume	778,493
Average Volume	768,561
Open	n/a
Previous Close	136.30
Day's Range	137.40 - 142.40
52-Week Range	92.40 - 152.10
Beta	-0.54
RSI	67.36
Earnings Date	Oct 29, 2025

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories that include oncology, hematology, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointesti...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,162
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In 2024, Beacon Pharmaceuticals's revenue was 10.70 billion, an increase of 25.76% compared to the previous year's 8.51 billion. Earnings were 521.01 million, an increase of 2.19%.